[tds_menu_login inline="yes" guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJwaG9uZSI6eyJtYXJnaW4tcmlnaHQiOiIyMCIsIm1hcmdpbi1ib3R0b20iOiIwIiwibWFyZ2luLWxlZnQiOiI2IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" toggle_hide="eyJwaG9uZSI6InllcyJ9" ia_space="eyJwaG9uZSI6IjAifQ==" icon_size="eyJhbGwiOjI0LCJwaG9uZSI6IjIwIn0=" avatar_size="eyJwaG9uZSI6IjIwIn0=" show_menu="yes" menu_offset_top="eyJwaG9uZSI6IjE4In0=" menu_offset_horiz="eyJhbGwiOjgsInBob25lIjoiLTMifQ==" menu_width="eyJwaG9uZSI6IjE4MCJ9" menu_horiz_align="eyJhbGwiOiJjb250ZW50LWhvcml6LWxlZnQiLCJwaG9uZSI6ImNvbnRlbnQtaG9yaXotcmlnaHQifQ==" menu_uh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_gh_padd="eyJwaG9uZSI6IjEwcHggMTVweCA4cHgifQ==" menu_ul_padd="eyJwaG9uZSI6IjhweCAxNXB4In0=" menu_ul_space="eyJwaG9uZSI6IjYifQ==" menu_ulo_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_gc_padd="eyJwaG9uZSI6IjhweCAxNXB4IDEwcHgifQ==" menu_bg="var(--news-hub-black)" menu_shadow_shadow_size="eyJwaG9uZSI6IjAifQ==" menu_arrow_color="rgba(0,0,0,0)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="var(--news-hub-white)" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_size="eyJwaG9uZSI6IjEyIn0=" f_uh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_links_font_size="eyJwaG9uZSI6IjEyIn0=" f_links_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_links_font_family="eyJwaG9uZSI6IjMyNSJ9" f_uf_font_size="eyJwaG9uZSI6IjEyIn0=" f_uf_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_uf_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_family="eyJwaG9uZSI6IjMyNSJ9" f_gh_font_size="eyJwaG9uZSI6IjEyIn0=" f_gh_font_line_height="eyJwaG9uZSI6IjEuMyJ9" f_btn1_font_family="eyJwaG9uZSI6IjMyNSJ9" f_btn1_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn1_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_weight="eyJwaG9uZSI6IjcwMCJ9" f_btn2_font_transform="eyJwaG9uZSI6InVwcGVyY2FzZSJ9" f_btn2_font_family="eyJwaG9uZSI6IjMyNSJ9"]
22.6 C
New York
[tds_menu_login guest_tdicon="td-icon-profile" logout_tdicon="td-icon-log-out" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn19" toggle_txt_color="var(--news-hub-white)" menu_offset_top="eyJhbGwiOiIxOSIsImxhbmRzY2FwZSI6IjE3IiwicG9ydHJhaXQiOiIxNSJ9" menu_offset_horiz="eyJhbGwiOi02LCJsYW5kc2NhcGUiOiItMyIsInBvcnRyYWl0IjoiLTIifQ==" menu_horiz_align="content-horiz-right" menu_bg="var(--news-hub-black)" menu_uh_color="var(--news-hub-light-grey)" menu_uh_border_color="var(--news-hub-dark-grey)" menu_ul_link_color="#ffffff" menu_ul_link_color_h="var(--news-hub-accent-hover)" menu_ul_sep_color="var(--news-hub-dark-grey)" menu_uf_txt_color="var(--news-hub-white)" menu_uf_txt_color_h="var(--news-hub-accent-hover)" menu_uf_border_color="var(--news-hub-dark-grey)" f_uh_font_family="325" f_uh_font_line_height="1.3" f_links_font_family="325" f_links_font_line_height="1.3" f_uf_font_line_height="1.3" f_uf_font_family="325" menu_uh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_ul_padd="eyJhbGwiOiIxOHB4IDI1cHgiLCJsYW5kc2NhcGUiOiIxNnB4IDIwcHgiLCJwb3J0cmFpdCI6IjhweCAxNXB4In0=" menu_ul_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" menu_ulo_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_shadow_shadow_size="0" menu_arrow_color="rgba(255,255,255,0)" menu_width="eyJhbGwiOiIyMjAiLCJwb3J0cmFpdCI6IjE4MCJ9" show_version="" menu_gh_padd="eyJhbGwiOiIyMHB4IDI1cHggMThweCIsImxhbmRzY2FwZSI6IjE1cHggMjBweCAxM3B4IiwicG9ydHJhaXQiOiIxMHB4IDE1cHggOHB4In0=" menu_gc_padd="eyJhbGwiOiIxOHB4IDI1cHggMjBweCIsImxhbmRzY2FwZSI6IjEzcHggMjBweCAxNXB4IiwicG9ydHJhaXQiOiI4cHggMTVweCAxMHB4In0=" menu_gh_color="var(--news-hub-light-grey)" menu_gh_border_color="var(--news-hub-dark-grey)" f_gh_font_family="325" menu_gc_btn1_bg_color="var(--news-hub-accent)" menu_gc_btn1_bg_color_h="var(--news-hub-accent-hover)" menu_gc_btn2_color="var(--news-hub-accent)" menu_gc_btn2_color_h="var(--news-hub-accent-hover)" f_btn1_font_family="325" f_btn1_font_transform="uppercase" f_btn2_font_family="325" f_btn2_font_transform="uppercase" f_btn1_font_weight="700" f_btn2_font_weight="700" show_menu="yes" f_uf_font_size="eyJsYW5kc2NhcGUiOiIxMiIsInBvcnRyYWl0IjoiMTIifQ==" icon_color="var(--news-hub-white)" icon_size="eyJhbGwiOjIyLCJsYW5kc2NhcGUiOiIyMCIsInBvcnRyYWl0IjoiMTgifQ==" avatar_size="eyJhbGwiOiIyMiIsImxhbmRzY2FwZSI6IjIwIiwicG9ydHJhaXQiOiIxOCJ9" ia_space="eyJhbGwiOiIxMCIsImxhbmRzY2FwZSI6IjgiLCJwb3J0cmFpdCI6IjYifQ==" f_toggle_font_family="325" f_toggle_font_size="eyJhbGwiOiIxNCIsImxhbmRzY2FwZSI6IjEzIiwicG9ydHJhaXQiOiIxMiJ9" logout_size="eyJhbGwiOjE0LCJsYW5kc2NhcGUiOiIxMyJ9" f_uh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_links_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ==" f_gh_font_size="eyJsYW5kc2NhcGUiOiIxMyIsInBvcnRyYWl0IjoiMTIifQ=="]
Deals

Lockly’s Flex Touch Google/Alexa smart lock with fingerprint access now $90 ($100 off, Today only)

9to5Toys.com - 0
Today only, as part of its Deals of the Day, Best Buy is offering a solid $100 price drop on the Lockly Flex Touch Smart Lock at $89.99 shipped. Regularly $190, this is a straight up $100 price drop and the lowest price we can find. Lockly’s official A...
Deals

Score the Worx Aerocart’s 8-in-1 functionality for outdoor jobs at $160 for today only (Reg. $230, 2024 low)

9to5Toys.com - 0
Courtesy of its Deals of the Day, Best Buy is offering the popular Worx Aerocart 8-In-1 Yard Cart for $159.99 shipped. You’ll normally find this handy yard cart at $230 most days, with discounts only dropping every few months. We’ve seen costs this yea...
News

Download: Apple Has Released iOS 18 Update To The General Public With Major Features

Wccftech.com - 0
After waiting for months, Apple has finally released the iOS 18 update for the iPhone to the general public with major features and changes. If you are a developer or an average user, you can download and install the latest build right now on your compatible devices. Apple has released iOS 18 and iPadOS 18 to the general public for all compatible iPhone and iPad models Apple first announced iOS 18 at its WWDC event in June; while it has been months, the update never showed any signs of downfall in terms of hype. Most of the hype is attached […]
Deals

Husqvarna’s electric 330iKE Combi Switch lawn edger hits new $293 low (Reg. $420)

9to5Toys.com - 0
Amazon is bringing down the costs on the Husqvarna 330iKE Battery Edger to $292.63 shipped, with the model more regularly fetching $420. Husqvarna is one of the higher-end tool brands that see less frequent discounts than others, with this model, in pa...

AMD Ryzen CPUs Dominate In Germany’s DIY Segment With 90% Market Share: X3D CPUs Selling Like Hotcakes

macOS 15 Sequoia: The Ars Technica review

Mice made transparent with a dye used in Doritos

TCL’s 2024 The Frame-style 65-inch Google Smart TV now $700 off for a new low at $1,300

AirPods 4 Reviews Reveal That The ANC Version Rivals The AirPods Pro 2, With The More Affordable Variant A Major Step-Up From The AirPods...

Razer Enki X Gaming Chair with adjustable recline, lumbar support, more is down to $300 (All-time low)

Starfield Shattered Space Gets Official Deep Dive Video

BMX meets e-mobility with Hyper’s Jet Fuel Step-Over e-bike at $600 low for today only (Reg. $1,000+)

Intel Next-Gen Cobra Core Architecture For Future x86 CPUs In The Works, Focuses on Higher Performance & Efficiency

DirecTV and Disney end blackout, claim they will offer better channel packages

Enjoy fresh herbs/veggies during colder months with AeroGarden’s indoor hydroponic systems from $60

Amazon offers wrinkle-free Van Heusen dress shirts and suit sets for the fam from $10 Prime shipped

Flappy Bird Creator Says He’s Not Involved In The Hit Game’s Return Amid References To NFTs and Crypto Arise

Star Wars Jedi: Survivor Update 9 Didn’t Resolve All Stuttering Issues

How To Craft Mythic Uniques In Diablo 4 Season 5

Sonic Fans Might Want To Go See The New Transformers Movie On Day One

Six AC outlets, two USB-C, and two USB-A ports adorn this 5-foot surge protector at only $10 (Reg. $18)

Omnipresent AI cameras will ensure good behavior, says Larry Ellison

Score exclusive $2,000 off Anker’s SOLIX F3800 LiFePo4 power station with expansion battery at $3,599 (Reg. $5,598+)

Nike’s Fall Flash Sale takes an extra 20% off select styles: Sneakers, apparel, more

News

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

Wccftech.com - 0
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]
Read more
News

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

Wccftech.com - 0
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]
Read more
News

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

Wccftech.com - 0
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]
Read more
News

Eli Lilly and Company’s Weight Loss Drug Zepbound Approved by FDA; Will Be Available at $1,060 Per 6 Doses

Wccftech.com - 0
The GLP-1 phenomenon is truly on the role, particularly in the US. Now, Eli Lilly and Company has moved one step closer to realizing the $100 billion annual sales potential for GLP-1 drugs by winning a key FDA approval. Eli Lilly and Company's Mounjaro (Tirzepatide) injections treat type-2 diabetes as well as obesity by targeting two hormones – Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) – to control blood sugar levels. Retatutide, another offering by Eli Lilly and Company, is currently undergoing clinical trials and supposedly offers superior results by targeting three different hunger-regulating hormones: GLP-1, GIP, and Glucagon. As […]
Read more
News

Wall Street is Downgrading Fitness Stocks Such as Peloton and Mooning Over GLP-1 Drug Makers Such as Eli Lilly and Company (LLY)

Wccftech.com - 0
The stock market is currently undergoing a thematic shift, one that favors weight loss drug manufacturers such as Eli Lilly and Company (LLY) over fitness-related names such as Peloton (PTON). Akin to a stone rolling down a hill, gathering momentum with each turn, such shifts represent generational wealth-making opportunities on the back of accelerating trends, as was witnessed when Netflix ushered in the age of content streaming or when Tesla popularized EVs as a crucial ingredient in combatting climate change. Eli Lilly and Company (LLY) Vs. Peloton (PTON) Eli Lilly and Company's Mounjaro injections treat type-2 diabetes as well as […]
Read more
News

GLP-1 Effect: Eli Lilly and Company (LLY) Smashes Q3 2023 Revenue Expectations on Weight Loss Drug Tailwind

Wccftech.com - 0
The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Co...
Read more
News

As the Quest for a Miracle Weight-Loss Drug Continues, Eli Lilly and Company Seems to Have an Edge Over Novo Nordisk’s Ozempic

Wccftech.com - 0

Americans are among the least healthy first-world citizens, partly due to the fact that over 42 percent of the adults in the US suffer from obesity – a condition that […]

Written by Rohail Saleem
Read more

Tag: Eli Lilly and Company

Will GLP-1 Weight Loss Drugs Allow Airlines to Save Millions of Dollars and Tank the Fast Food Industry? Here are the Numbers So Far

News
GLP-1 weight loss drugs and the ongoing advances in the AI sphere are currently two of the biggest thematic plays that Wall Street is relentlessly championing, facilitating a phenomenal influx of capital in companies that are seen as beneficiaries of the upheaval that the proponents of these nascent technologies argue is just around the proverbial corner. Recently, GLP-1 drugs from the likes of Novo Nordisk (NVO) and Eli Lilly and Company (LLY) have been billed as a blessing in disguise for the airline industry and a harbinger of doom for the fast food sector. Can a single drug really induce […]

GLP-1 Drug War: Obese Patients Are Typically Twice as Likely To Lose 15% Or More of Their Body Weight With Eli Lilly and Company’s...

News
With around $100 billion in annual sales by the end of this decade up for grabs, the GLP-1 drug war for the global waistline is heating up. Around two weeks back, Novo Nordisk created a media spectacle out of a study that claimed its GLP-1 weight loss drug could slash death risk from heart disease by up to 20 percent. This salvo was apparently fired in response to the steeply discounted price at which Eli Lilly and Company began marketing its own GLP-1 drug. Well, today, the American pharma giant is again attacking Novo Nordisk's proverbial front lines, resplendent in […]

Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug

News
A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 weight loss drug at a substantial discount to a competing offering by Novo Nordisk. The Danish pharmaceutical giant has now responded by hyping up the results of a critical trial. Glucagon-Like Peptide-1, or GLP-1 for short, plays an important role in regulating hunger. This hormone forms the bedrock of Novo Nordisk's Ozempic and Wegovy […]

Eli Lilly and Company’s Weight Loss Drug Zepbound Approved by FDA; Will Be Available at $1,060 Per 6 Doses

News
The GLP-1 phenomenon is truly on the role, particularly in the US. Now, Eli Lilly and Company has moved one step closer to realizing the $100 billion annual sales potential for GLP-1 drugs by winning a key FDA approval. Eli Lilly and Company's Mounjaro (Tirzepatide) injections treat type-2 diabetes as well as obesity by targeting two hormones – Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) – to control blood sugar levels. Retatutide, another offering by Eli Lilly and Company, is currently undergoing clinical trials and supposedly offers superior results by targeting three different hunger-regulating hormones: GLP-1, GIP, and Glucagon. As […]

Wall Street is Downgrading Fitness Stocks Such as Peloton and Mooning Over GLP-1 Drug Makers Such as Eli Lilly and Company (LLY)

News
The stock market is currently undergoing a thematic shift, one that favors weight loss drug manufacturers such as Eli Lilly and Company (LLY) over fitness-related names such as Peloton (PTON). Akin to a stone rolling down a hill, gathering momentum with each turn, such shifts represent generational wealth-making opportunities on the back of accelerating trends, as was witnessed when Netflix ushered in the age of content streaming or when Tesla popularized EVs as a crucial ingredient in combatting climate change. Eli Lilly and Company (LLY) Vs. Peloton (PTON) Eli Lilly and Company's Mounjaro injections treat type-2 diabetes as well as […]

GLP-1 Effect: Eli Lilly and Company (LLY) Smashes Q3 2023 Revenue Expectations on Weight Loss Drug Tailwind

News
The GLP-1 mania is in full swing now, as evidenced by Eli Lilly and Company (NYSE: LLY) smashing consensus expectations for its top-line and bottom-line metrics in Q3 2023, aided by the soaring demand for its Mounjaro weight loss drug. Eli Lilly and Co...

As the Quest for a Miracle Weight-Loss Drug Continues, Eli Lilly and Company Seems to Have an Edge Over Novo Nordisk’s Ozempic

News

Americans are among the least healthy first-world citizens, partly due to the fact that over 42 percent of the adults in the US suffer from obesity – a condition that […]

Written by Rohail Saleem
12Page 2 of 2

Recent articles

spot_img

©Patti.tech 2022